- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05645211
어린이의 AgRP 및 GH/IGF-1 축
아구티 관련 펩타이드(AgRP)와 어린이의 GH/IGF-1 축
Recent data support the existence of a GH-Agouti-related peptide (AgRP) axis. The neuropeptide AgRP promotes food intake and has important effects on energy homeostasis. Recent evidence suggest that GH stimulates AgRP and AgRP may mediate some of GH's important nutritional and metabolic effects. main goals of this project are to characterize, for the first time, plasma levels of AgRP in children and to determine how these relate to GH and IGF-1 levels, age, body composition, clinical and other endocrine parameters. To accomplish this, we will conduct two studies, one being a cross-sectional study that will measure AgRP levels in 140 healthy children ages 5-17 and the second being a prospective study that will measure the change in plasma AgRP levels in response to GH treatment in 16 children who receive this as part of their clinical care for GH deficiency or short stature.
연구 개요
상태
정황
상세 설명
Protocol 1 This will be a cross-sectional study in 140 healthy children. Participation will include one visit that will take place between 8-9 am and after a fast from midnight the night before.
Procedures at the visit will include:
- Review of medical history
- Anthropometrics measurements: Weight, height, waist and hip circumferences.
- Collection of information from medical record including growth records and physical examination findings including features relevant to pubertal stage in all children and onset of menses in females.
- Assessment of pubertal status and Tanner stage based on physical examination.
- Collection of information on diet, activity level and sleep.
- Blood Sampling: venous blood will be sampled from a peripheral vein for measurement of AgRP, GH, IGF-1, leptin, SOb-R, triglycerides, insulin, glucose, testosterone(males), estradiol(females), DHEAS and cortisol levels. Insulin and glucose levels will be used to assess insulin resistance by HOMA & QUICKI.
Protocol 2 This will be a prospective study in 16 children who will be studied before and at 4 time points (1 week, 2 weeks, 1 month and 2 months) after starting GH treatment as part of their clinical care. This protocol will study subjects Groups 2 and 3. Growth hormone will not be prescribed as part of this study. Children will be treated clinically with GH as prescribed by their Pediatric Endocrinologist for FDA approved indications and according to standard guidelines for dosing for treatment of GH deficiency in children.
Each visit that will take place between 8-9 am and after a fast from midnight the night before.
Procedures at each visit will include:
- Review of medical history
- Anthropometrics measurements: Weight, height, waist and hip circumferences, skinfold thicknesses.
- Collection of information from medical record including growth records and physical examination findings including features relevant to pubertal stage in all children and onset of menses in females. GH dose and compliance will be recorded at follow up visits.
- Collection of information on diet, activity level and sleep.
- Blood Sampling: Venous blood will be sampled at a peripheral vein for:
Baseline (pre-GH treatment): measurement of AgRP, GH, IGF-1, IGFBP-3, leptin, SOb-R, triglycerides, insulin and glucose, testosterone(males), estradiol(females), DHEAS and cortisol levels.
Follow up visits on growth hormone: measurement of AgRP, IGF-1, IGFBP-3, leptin, SOb-R, triglycerides, insulin, glucose and cortisol levels.
Insulin and glucose levels will be used to assess insulin resistance by HOMA & QUICKI.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Pamela Freda
- 전화번호: 2123052254
- 이메일: puf1@cumc.columbia.edu
연구 연락처 백업
- 이름: Rosa Lazarte
- 전화번호: 2123054921
- 이메일: rl2345@cumc.columbia.edu
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Healthy children: 140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center.Children will be recruited from among the healthy children visiting primary care Pediatricians at our medical center.
GH deficient and idiopathic short stature children: 16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature. They will be representative of the diverse racial and ethnic mix of our hospital's patient population.
설명
Healthy children
Inclusion Criteria:
- Ambulatory male and female children aged 5-17 years
- Normal weight at birth
- Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.
Exclusion Criteria:
- Genetic defects, chronic illnesses.
- Current prescription medication use
- Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry.
Children with GH deficiency:
Inclusion Criteria:
- Ambulatory male and female children aged 5-9 years who are prepubertal
- Normal weight at birth
- Growth failure
- Peak GH response to 2 GH stimulation tests < 10 ng/ml
- Normal renal and liver function
Exclusion criteria:
- Multiple pituitary hormone deficiencies,
- GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
- History of diabetes or malignancy
- Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.
Children with idiopathic Short Stature:
Inclusion Criteria:
- Ambulatory male and female children aged 5-9 years who are prepubertal
- Normal weight at birth
- Height >2.25 SD below mean for age
- Peak GH response to 2 stimulation tests >10 ng/ml or normal IGF-1 and IGFBP-3 levels
- No prior supplemental growth hormone exposure
- Normal renal and liver function
Exclusion criteria:
- Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
- History of diabetes or malignancy
- Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: CROSS_SECTIONAL
코호트 및 개입
그룹/코호트 |
|---|
|
Group 1: Healthy children
140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center. Inclusion Criteria:
Exclusion Criteria:
|
|
Group 2: Children with GH deficiency
16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature. They will be representative of the diverse racial and ethnic mix of our hospital's patient population. GH deficiency: Inclusion Criteria:
Exclusion criteria:
|
|
Group 3: Children with short stature
Idiopathic Short Stature: Inclusion Criteria:
Exclusion criteria:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Protocol 1: Correlation of Plasma AgRP levels with IGF-1 levels
기간: Baseline (cross-sectional at single time point, no intervention)
|
Plasma AgRP levels correlation with IGF-1 levels Protocol 1: Correlation of Plasma AgRP levels with IGF-1 levels |
Baseline (cross-sectional at single time point, no intervention)
|
|
Protocol 2: Change in plasma AgRP levels with GH therapy
기간: baseline to 2 months
|
Change in plasma AgRP levels from pre-GH therapy to post-GH therapy |
baseline to 2 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Protocol 1: Correlation of plasma AgRP levels with age
기간: Baseline (cross-sectional testing at one time point, no intervention)
|
Correlation of plasma AgRP levels with age |
Baseline (cross-sectional testing at one time point, no intervention)
|
|
Protocol 1: Correlation of plasma AgRP levels with leptin levels
기간: Baseline (cross-sectional testing at one time point, no intervention)
|
Correlation of plasma AgRP levels with leptin levels |
Baseline (cross-sectional testing at one time point, no intervention)
|
|
Protocol 1: Correlation of plasma AgRP with percent body fat (determined from skinfold thickness)
기간: Baseline (cross-sectional testing at one time point, no intervention)
|
Correlation of plasma AgRP with percent body fat (determined from skinfold thickness) |
Baseline (cross-sectional testing at one time point, no intervention)
|
|
Protocol 2: Change in AgRP levels correlation with change in IGF-1 levels
기간: Baseline to 2 months
|
Correlation of change in AgRP levels with change in IGF-1 levels from baseline to 2 months of GH therapy |
Baseline to 2 months
|
|
Protocol 2: Change in AgRP level correlation with pre-treatment leptin levels
기간: Baseline to 2 months
|
Correlation of change in AgRP level from baseline to 2 months of GH therapy with pre-treatment leptin levels |
Baseline to 2 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .